Streptococcus salivarius K12 and Improved Blood Clinical Chemistry

Doses used in studies

CFU/day: 10 billion (median 10 billion, IQR 10 billion–10 billion) — 1 study

Safety in these studies

Overall tolerabilityNo significant difference
No statistically significant differences between the probiotic and placebo treated groups were detected in either the blood clinical chemistry or hematology results (P>0.05).
from: Evaluation of safety and human tolerance of the oral probiotic Streptococcus salivarius K1
Overall tolerabilityReported
The questionnaire responses of the subjects indicated that both treatments were well tolerated.
from: Evaluation of safety and human tolerance of the oral probiotic Streptococcus salivarius K1

1 of 1 paper

Evaluation of safety and human tolerance of the oral probiotic Streptococcus salivarius K12: a randomized, placebo-controlled, double-blind study.